About this Research Topic
The fight against solid tumors has seen significant advances in recent years, yet achieving optimal therapeutic outcomes remains challenging. Clinical evidence consistently shows that combination therapies, which merge classical anticancer agents, targeted treatments, and immunomodulatory drugs, often outperform monotherapies in effectiveness. Rationally designing these combinations to maximize efficacy while minimizing toxicity is a critical objective in oncology. Furthermore, repurposing drugs approved for non-cancer indications to enhance existing cancer treatments offers a promising avenue for innovation. Understanding how to leverage these combinations can significantly improve patient outcomes and push the boundaries of current cancer therapy.
The goal of this Research Topic is to explore rational combination therapies for solid tumors to uncover strategies that maximize therapeutic efficacy and minimize side effects. We aim to provide a platform for both clinical and preclinical studies that examine the synergy between various drugs, including those not traditionally associated with cancer treatment. Focus areas include combinations targeting tumors with specific unfavorable mutations, combinations with drugs developed for other diseases, and strategies to overcome resistance. Additionally, we seek insights into the interplay between immunotherapy and targeted therapies, as well as approaches that integrate drugs affecting cell metabolism or DNA repair with traditional anticancer agents. By addressing these complex interactions, we hope to foster a deeper understanding of how to construct effective combination therapies that can revolutionize cancer treatment.
We invite researchers and clinicians to contribute original research articles, reviews, case reports, and clinical studies focusing on various aspects of combination therapies for solid tumors. Specific themes of interest include, but are not limited to:
• Combinations targeting tumors with specific unfavorable mutations
• Combining drugs initially marketed for different pathologies
• Strategies to overcome drug resistance
• Integrating immunotherapy with targeted therapies
• Combinations of drugs that interfere with cell metabolism alongside anticancer agents
• Combinations of drugs that disrupt DNA repair mechanisms with anticancer agents
Manuscripts should contribute to the understanding and development of rational combination therapies, proposing innovative solutions to enhance treatment efficacy and reduce toxicity. By aggregating diverse insights and data, we aim to establish a comprehensive knowledge base that can guide future therapeutic strategies for solid tumors.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The goal of this Research Topic is to explore rational combination therapies for solid tumors to uncover strategies that maximize therapeutic efficacy and minimize side effects. We aim to provide a platform for both clinical and preclinical studies that examine the synergy between various drugs, including those not traditionally associated with cancer treatment. Focus areas include combinations targeting tumors with specific unfavorable mutations, combinations with drugs developed for other diseases, and strategies to overcome resistance. Additionally, we seek insights into the interplay between immunotherapy and targeted therapies, as well as approaches that integrate drugs affecting cell metabolism or DNA repair with traditional anticancer agents. By addressing these complex interactions, we hope to foster a deeper understanding of how to construct effective combination therapies that can revolutionize cancer treatment.
We invite researchers and clinicians to contribute original research articles, reviews, case reports, and clinical studies focusing on various aspects of combination therapies for solid tumors. Specific themes of interest include, but are not limited to:
• Combinations targeting tumors with specific unfavorable mutations
• Combining drugs initially marketed for different pathologies
• Strategies to overcome drug resistance
• Integrating immunotherapy with targeted therapies
• Combinations of drugs that interfere with cell metabolism alongside anticancer agents
• Combinations of drugs that disrupt DNA repair mechanisms with anticancer agents
Manuscripts should contribute to the understanding and development of rational combination therapies, proposing innovative solutions to enhance treatment efficacy and reduce toxicity. By aggregating diverse insights and data, we aim to establish a comprehensive knowledge base that can guide future therapeutic strategies for solid tumors.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: combination therapies, solid tumors, drug resistance, immunotherapy, targeted therapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
